Is Abionyx Pharma SA halal to invest in?

According to Musaffa's Shariah screening methodology, Abionyx Pharma SA (ABNX.PA) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Abionyx Pharma SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Abionyx Pharma SA using these criteria to determine its compliance status.

Can Muslims buy shares of Abionyx Pharma SA?

Muslim investors may consider investing in Abionyx Pharma SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Abionyx Pharma SA classified as HALAL?

Musaffa determines the Shariah status of Abionyx Pharma SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Abionyx Pharma SA updated?

The Shariah compliance status of Abionyx Pharma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Abionyx Pharma SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Abionyx Pharma SA?

You can check the latest Shariah compliance status of Abionyx Pharma SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Abionyx Pharma SA ABNX.PA

€3.59 €0.08 (2.18%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ABNX.PA Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: February 04, 2026

Report Source: 2025 2nd Quarter Report

Abionyx Pharma SA. Stock Analysis ABNX.PA

France Health Care Micro Cap Report: Q2, 2025

ABIONYX Pharma SA engages in the discovery and development of novel therapies for patients without existing or effective treatments. The company employs 49 full-time employees The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Key Statistics of Abionyx Pharma SA (ABNX.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€3.59€3.73

Today's Open

€3.67

Volume

80.78K

P/E Ratio (TTM)

52 Week Range

€1.17€5.29

Market Cap

120.13M

Avg. Volume

14.56K

Dividend Yield

Financial Metrics & Statements of Abionyx Pharma SA (ABNX.PA)

Community-Curated Collections with Abionyx Pharma SA (ABNX.PA) ( With ABNX.PA )

View All

Community-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.

My Watchlist

By Adam ATIR

0 Followers

+181 more

FAQ's for Abionyx Pharma SA (ABNX.PA)

According to Musaffa’s Shariah screening methodology, Abionyx Pharma SA (ABNX.PA) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.